Laura Cristoferi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2321012/publications.pdf

Version: 2024-02-01

44	638	623734	642732
papers	citations	14 h-index	23 g-index

47	47	47	821
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	8.1	103
2	Outcome of COVIDâ€19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology, 2021, 73, 2099-2109.	7.3	56
3	Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. Hepatology Communications, 2020, 4, 1257-1262.	4.3	55
4	Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Digestive Diseases, 2015, 33, 140-148.	1.9	36
5	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
6	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
7	Prevalence of upper gastrointestinal endoscopic findings in the community: A systematic review of studies in unselected samples of subjects. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1527-1538.	2.8	30
8	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in NaÃ¯ve Patients With Primary Biliary Cholangitis: A Dual Cutâ€Off Approach. Hepatology, 2021, 74, 1496-1508.	7.3	28
9	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	1.3	27
10	Effects of immunosuppressive drugs on COVIDâ€19 severity in patients with autoimmune hepatitis. Liver International, 2022, 42, 607-614.	3.9	26
11	The immunobiology of female predominance in primary biliary cholangitis. Journal of Autoimmunity, 2018, 95, 124-132.	6.5	24
12	Prognostic models in primary biliary cholangitis. Journal of Autoimmunity, 2018, 95, 171-178.	6.5	22
13	New Therapeutic Targets in Autoimmune Cholangiopathies. Frontiers in Medicine, 2020, 7, 117.	2.6	22
14	Systematic reviewâ€"pancreatic involvement in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1478-1491.	3.7	18
15	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. International Journal of Environmental Research and Public Health, 2020, 17, 3095.	2.6	17
16	Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. Journal of Hepatology, 2020, 73, 965-966.	3.7	14
17	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. Annals of Hepatology, 2020, 19, 5-16.	1.5	13
18	The Role of Epigenetics in Primary Biliary Cholangitis. International Journal of Molecular Sciences, 2022, 23, 4873.	4.1	11

#	Article	IF	Citations
19	Precision medicine in primary biliary cholangitis. Journal of Digestive Diseases, 2019, 20, 338-345.	1.5	9
20	Geoepidemiology and (epi-)genetics in primary biliary cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 11-15.	2.4	8
21	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. Inflammatory Bowel Diseases, 2020, 26, e138-e139.	1.9	8
22	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. Journal of Translational Autoimmunity, 2021, 4, 100081.	4.0	7
23	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver International, 2022, 42, 615-627.	3.9	7
24	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. Journal of Autoimmunity, 2020, 113, 102503.	6.5	5
25	An update on novel pharmacological agents for primary sclerosing cholangitis. Expert Opinion on Therapeutic Targets, 2022, 26, 69-77.	3.4	5
26	Antiâ€gp210 and other antiâ€nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know. Liver International, 2021, 41, 432-435.	3.9	4
27	A Smooth Esophageal Stricture Causing Dysphagia. Dysphagia, 2018, 33, 399-402.	1.8	3
28	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1415-1422.	3.8	3
29	Individualizing Care. Clinics in Liver Disease, 2018, 22, 545-561.	2.1	3
30	Transient elastography in chronic liver disease: Beware of the cut-offs!. Journal of Hepatology, 2021, 75, 1245-1246.	3.7	3
31	Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group. Digestive and Liver Disease, 2020, 52, e32.	0.9	2
32	Risk stratification in primary sclerosing cholangitis. Minerva Gastroenterology, 2020, , .	0.5	2
33	Comment on â€œEarly Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysisâ€. Disease Markers, 2020, 2020, 1-2.	1.3	1
34	THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis. Journal of Hepatology, 2019, 70, e165.	3.7	0
35	FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study. Journal of Hepatology, 2019, 70, e386.	3.7	0
36	Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis. Digestive and Liver Disease, 2019, 51, e18.	0.9	0

#	Article	IF	Citations
37	FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. Journal of Hepatology, 2019, 70, e387-e388.	3.7	0
38	Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. Digestive and Liver Disease, 2019, 51, e1.	0.9	0
39	Individualizing Care. Surgical Oncology Clinics of North America, 2020, 29, 87-103.	1.5	0
40	Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?. Journal of Translational Autoimmunity, 2021, 4, 100124.	4.0	0
41	Elastography in Autoimmune Liver Diseases. , 2021, , 91-103.		0
42	Antioxidant Treatment for Acute Pancreatitis. Recent Patents on Inflammation and Allergy Drug Discovery, 2014, 8, 154-161.	3.6	0
43	PTU-46â€...Safety and efficacy of fully covered metallic stent placement for patients with primary sclerosing cholangitis. , 2021, , .		0
44	X marks the spot in autoimmunity. Expert Review of Clinical Immunology, 2022, 18, 429-437.	3.0	0